Prognostic role of pre-diagnostic circulating inflammatory biomarkers in breast cancer survival: evidence from the EPIC cohort study

Carlota Castro-Espin; Manon Cairat; Anne-Sophie Navionis; Christina C Dahm; Christian S Antoniussen; Anne Tjønneland; Lene Mellemkjær; Francesca Romana Mancini; Mariem Hajji-Louati; Gianluca Severi; Charlotte Le Cornet; Rudolf Kaaks; Matthias B Schulze; Giovanna Masala; Claudia Agnoli; Carlotta Sacerdote; Marta Crous-Bou; Maria-Jose Sánchez; Pilar Amiano; María-Dolores Chirlaque; Marcela Guevara; Karl Smith-Byrne; Alicia K Heath; Sofia Christakoudi; Marc J Gunter; Sabina Rinaldi; Antonio Agudo; Laure Dossus

doi:10.1038/s41416-024-02858-6

Prognostic role of pre-diagnostic circulating inflammatory biomarkers in breast cancer survival: evidence from the EPIC cohort study

Carlota Castro-Espin, Manon Cairat, Anne-Sophie Navionis, Christina C Dahm, Christian S Antoniussen, Anne Tjønneland, Lene Mellemkjær, Francesca Romana Mancini, Mariem Hajji-Louati, Gianluca Severi, Charlotte Le Cornet, Rudolf Kaaks, Matthias B Schulze, Giovanna Masala, Claudia Agnoli, Carlotta Sacerdote, Marta Crous-Bou, Maria-Jose Sánchez, Pilar Amiano, María-Dolores ChirlaqueMarcela Guevara, Karl Smith-Byrne, Alicia K Heath, Sofia Christakoudi, Marc J Gunter, Sabina Rinaldi, Antonio Agudo, Laure Dossus

Afdeling for Miljø og Sundhed

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › peer review

5 Citationer (Scopus)

39 Downloads (Pure)

Abstract

Background
Inflammation influences tumour progression and cancer prognosis, but its role preceding breast cancer (BC) and its prognostic implications remain inconclusive.

Methods
We studied pre-diagnostic plasma inflammatory biomarkers in 1538 women with BC from the EPIC study. Cox proportional hazards models assessed their relationship with all-cause and BC-specific mortality, adjusting for tumour characteristics and lifestyle factors.

Results
Over a 7-year follow-up after diagnosis, 229 women died, 163 from BC. Elevated IL-6 levels were associated with increased all-cause mortality risk (HR1-SD 1.25, 95% CI 1.07–1.47). Among postmenopausal, IL-6 was associated with higher all-cause (HR1-SD 1.41, 95% CI 1.18–1.69) and BC-specific mortality (HR1-SD 1.31, 95% CI 1.03–1.66), (PHeterogeneity (pre/postmenopausal) < 0.05 for both), while IL-10 and TNFα were associated with all-cause mortality only (HR1-SD 1.19, 95% CI 1.02–1.40 and HR1-SD 1.28, 95% CI 1.06–1.56). Among ER+PR+, IL-10 was associated with all-cause and BC-specific mortality (HR1-SD 1.35, 95% CI 1.10–1.65 and HR1-SD 1.42 95% CI 1.08–1.86), while TNF-α was associated with all-cause mortality in HER2- (HR1-SD 1.31, 95% CI 1.07–1.61). An inflammatory score predicted higher all-cause mortality, especially in postmenopausal women (HR1-SD 1.30, 95% CI 1.07–1.58).

Conclusions
Higher pre-diagnosis IL-6 levels suggest poorer long-term survival among BC survivors. In postmenopausal survivors, elevated IL-6, IL-10, and TNFα and inflammatory scores seem to predict all-cause mortality.

Originalsprog	Engelsk
Tidsskrift	British Journal of Cancer
Vol/bind	131
Udgave nummer	9
Sider (fra-til)	1496-1505
Antal sider	10
ISSN	0007-0920
DOI	https://doi.org/10.1038/s41416-024-02858-6
Status	Udgivet - 2024

Bibliografisk note

Adgang til dokumentet

10.1038/s41416-024-02858-6Licens: CC BY

FulltextForlagets udgivne version, 1,09 MBLicens: CC BY

Biblioteksadgang?

Tjek tilgængelighed hos det Kgl. Bibliotek

Citationsformater

Castro-Espin, C., Cairat, M., Navionis, A.-S., Dahm, C. C., Antoniussen, C. S., Tjønneland, A., Mellemkjær, L., Mancini, F. R., Hajji-Louati, M., Severi, G., Le Cornet, C., Kaaks, R., Schulze, M. B., Masala, G., Agnoli, C., Sacerdote, C., Crous-Bou, M., Sánchez, M.-J., Amiano, P., ... Dossus, L. (2024). Prognostic role of pre-diagnostic circulating inflammatory biomarkers in breast cancer survival: evidence from the EPIC cohort study. British Journal of Cancer, 131(9), 1496-1505. https://doi.org/10.1038/s41416-024-02858-6

Castro-Espin, C, Cairat, M, Navionis, A-S, Dahm, CC, Antoniussen, CS, Tjønneland, A, Mellemkjær, L, Mancini, FR, Hajji-Louati, M, Severi, G, Le Cornet, C, Kaaks, R, Schulze, MB, Masala, G, Agnoli, C, Sacerdote, C, Crous-Bou, M, Sánchez, M-J, Amiano, P, Chirlaque, M-D, Guevara, M, Smith-Byrne, K, Heath, AK, Christakoudi, S, Gunter, MJ, Rinaldi, S, Agudo, A & Dossus, L 2024, 'Prognostic role of pre-diagnostic circulating inflammatory biomarkers in breast cancer survival: evidence from the EPIC cohort study', British Journal of Cancer, bind 131, nr. 9, s. 1496-1505. https://doi.org/10.1038/s41416-024-02858-6

@article{226c70fd1b5b43dabd0c3e4386029794,

title = "Prognostic role of pre-diagnostic circulating inflammatory biomarkers in breast cancer survival: evidence from the EPIC cohort study",

abstract = "BACKGROUND: Inflammation influences tumour progression and cancer prognosis, but its role preceding breast cancer (BC) and its prognostic implications remain inconclusive.METHODS: We studied pre-diagnostic plasma inflammatory biomarkers in 1538 women with BC from the EPIC study. Cox proportional hazards models assessed their relationship with all-cause and BC-specific mortality, adjusting for tumour characteristics and lifestyle factors.RESULTS: Over a 7-year follow-up after diagnosis, 229 women died, 163 from BC. Elevated IL-6 levels were associated with increased all-cause mortality risk (HR1-SD 1.25, 95% CI 1.07-1.47). Among postmenopausal, IL-6 was associated with higher all-cause (HR1-SD 1.41, 95% CI 1.18-1.69) and BC-specific mortality (HR1-SD 1.31, 95% CI 1.03-1.66), (PHeterogeneity (pre/postmenopausal) < 0.05 for both), while IL-10 and TNFα were associated with all-cause mortality only (HR1-SD 1.19, 95% CI 1.02-1.40 and HR1-SD 1.28, 95% CI 1.06-1.56). Among ER+PR+, IL-10 was associated with all-cause and BC-specific mortality (HR1-SD 1.35, 95% CI 1.10-1.65 and HR1-SD 1.42 95% CI 1.08-1.86), while TNF-α was associated with all-cause mortality in HER2- (HR1-SD 1.31, 95% CI 1.07-1.61). An inflammatory score predicted higher all-cause mortality, especially in postmenopausal women (HR1-SD 1.30, 95% CI 1.07-1.58).CONCLUSIONS: Higher pre-diagnosis IL-6 levels suggest poorer long-term survival among BC survivors. In postmenopausal survivors, elevated IL-6, IL-10, and TNFα and inflammatory scores seem to predict all-cause mortality.",

keywords = "Humans, Female, Breast Neoplasms/mortality, Middle Aged, Prognosis, Inflammation/blood, Biomarkers, Tumor/blood, Interleukin-6/blood, Aged, Postmenopause/blood, Cohort Studies, Interleukin-10/blood, Adult, Tumor Necrosis Factor-alpha/blood, Proportional Hazards Models",

author = "Carlota Castro-Espin and Manon Cairat and Anne-Sophie Navionis and Dahm, {Christina C} and Antoniussen, {Christian S} and Anne Tj{\o}nneland and Lene Mellemkj{\ae}r and Mancini, {Francesca Romana} and Mariem Hajji-Louati and Gianluca Severi and {Le Cornet}, Charlotte and Rudolf Kaaks and Schulze, {Matthias B} and Giovanna Masala and Claudia Agnoli and Carlotta Sacerdote and Marta Crous-Bou and Maria-Jose S{\'a}nchez and Pilar Amiano and Mar{\'i}a-Dolores Chirlaque and Marcela Guevara and Karl Smith-Byrne and Heath, {Alicia K} and Sofia Christakoudi and Gunter, {Marc J} and Sabina Rinaldi and Antonio Agudo and Laure Dossus",

note = "{\textcopyright} 2024. The Author(s).",

year = "2024",

doi = "10.1038/s41416-024-02858-6",

language = "English",

volume = "131",

pages = "1496--1505",

journal = "British Journal of Cancer",

issn = "0007-0920",

publisher = "nature publishing group",

number = "9",

}

TY - JOUR

T1 - Prognostic role of pre-diagnostic circulating inflammatory biomarkers in breast cancer survival

T2 - evidence from the EPIC cohort study

AU - Castro-Espin, Carlota

AU - Cairat, Manon

AU - Navionis, Anne-Sophie

AU - Dahm, Christina C

AU - Antoniussen, Christian S

AU - Tjønneland, Anne

AU - Mellemkjær, Lene

AU - Mancini, Francesca Romana

AU - Hajji-Louati, Mariem

AU - Severi, Gianluca

AU - Le Cornet, Charlotte

AU - Kaaks, Rudolf

AU - Schulze, Matthias B

AU - Masala, Giovanna

AU - Agnoli, Claudia

AU - Sacerdote, Carlotta

AU - Crous-Bou, Marta

AU - Sánchez, Maria-Jose

AU - Amiano, Pilar

AU - Chirlaque, María-Dolores

AU - Guevara, Marcela

AU - Smith-Byrne, Karl

AU - Heath, Alicia K

AU - Christakoudi, Sofia

AU - Gunter, Marc J

AU - Rinaldi, Sabina

AU - Agudo, Antonio

AU - Dossus, Laure

PY - 2024

Y1 - 2024

N2 - BACKGROUND: Inflammation influences tumour progression and cancer prognosis, but its role preceding breast cancer (BC) and its prognostic implications remain inconclusive.METHODS: We studied pre-diagnostic plasma inflammatory biomarkers in 1538 women with BC from the EPIC study. Cox proportional hazards models assessed their relationship with all-cause and BC-specific mortality, adjusting for tumour characteristics and lifestyle factors.RESULTS: Over a 7-year follow-up after diagnosis, 229 women died, 163 from BC. Elevated IL-6 levels were associated with increased all-cause mortality risk (HR1-SD 1.25, 95% CI 1.07-1.47). Among postmenopausal, IL-6 was associated with higher all-cause (HR1-SD 1.41, 95% CI 1.18-1.69) and BC-specific mortality (HR1-SD 1.31, 95% CI 1.03-1.66), (PHeterogeneity (pre/postmenopausal) < 0.05 for both), while IL-10 and TNFα were associated with all-cause mortality only (HR1-SD 1.19, 95% CI 1.02-1.40 and HR1-SD 1.28, 95% CI 1.06-1.56). Among ER+PR+, IL-10 was associated with all-cause and BC-specific mortality (HR1-SD 1.35, 95% CI 1.10-1.65 and HR1-SD 1.42 95% CI 1.08-1.86), while TNF-α was associated with all-cause mortality in HER2- (HR1-SD 1.31, 95% CI 1.07-1.61). An inflammatory score predicted higher all-cause mortality, especially in postmenopausal women (HR1-SD 1.30, 95% CI 1.07-1.58).CONCLUSIONS: Higher pre-diagnosis IL-6 levels suggest poorer long-term survival among BC survivors. In postmenopausal survivors, elevated IL-6, IL-10, and TNFα and inflammatory scores seem to predict all-cause mortality.

AB - BACKGROUND: Inflammation influences tumour progression and cancer prognosis, but its role preceding breast cancer (BC) and its prognostic implications remain inconclusive.METHODS: We studied pre-diagnostic plasma inflammatory biomarkers in 1538 women with BC from the EPIC study. Cox proportional hazards models assessed their relationship with all-cause and BC-specific mortality, adjusting for tumour characteristics and lifestyle factors.RESULTS: Over a 7-year follow-up after diagnosis, 229 women died, 163 from BC. Elevated IL-6 levels were associated with increased all-cause mortality risk (HR1-SD 1.25, 95% CI 1.07-1.47). Among postmenopausal, IL-6 was associated with higher all-cause (HR1-SD 1.41, 95% CI 1.18-1.69) and BC-specific mortality (HR1-SD 1.31, 95% CI 1.03-1.66), (PHeterogeneity (pre/postmenopausal) < 0.05 for both), while IL-10 and TNFα were associated with all-cause mortality only (HR1-SD 1.19, 95% CI 1.02-1.40 and HR1-SD 1.28, 95% CI 1.06-1.56). Among ER+PR+, IL-10 was associated with all-cause and BC-specific mortality (HR1-SD 1.35, 95% CI 1.10-1.65 and HR1-SD 1.42 95% CI 1.08-1.86), while TNF-α was associated with all-cause mortality in HER2- (HR1-SD 1.31, 95% CI 1.07-1.61). An inflammatory score predicted higher all-cause mortality, especially in postmenopausal women (HR1-SD 1.30, 95% CI 1.07-1.58).CONCLUSIONS: Higher pre-diagnosis IL-6 levels suggest poorer long-term survival among BC survivors. In postmenopausal survivors, elevated IL-6, IL-10, and TNFα and inflammatory scores seem to predict all-cause mortality.

KW - Humans

KW - Female

KW - Breast Neoplasms/mortality

KW - Middle Aged

KW - Prognosis

KW - Inflammation/blood

KW - Biomarkers, Tumor/blood

KW - Interleukin-6/blood

KW - Aged

KW - Postmenopause/blood

KW - Cohort Studies

KW - Interleukin-10/blood

KW - Adult

KW - Tumor Necrosis Factor-alpha/blood

KW - Proportional Hazards Models

U2 - 10.1038/s41416-024-02858-6

DO - 10.1038/s41416-024-02858-6

M3 - Journal article

C2 - 39342063

SN - 0007-0920

VL - 131

SP - 1496

EP - 1505

JO - British Journal of Cancer

JF - British Journal of Cancer

IS - 9

ER -